Importantly, we found that DMXAA treatment significantly increased the proportion of (CD11b− CD3+) CD8+ T cells without significantly changing the proportion of (CD11b− CD3+) CD4+ T cells in the bone marrow tumor microenvironment (Fig. 6f). The gene discussed is CD4; the disease is neoplasm.